Priced for a smaller company: management is quietly telling investors the business has already outgrown what the numbers
The model's full reasoning — Q4 2015 call → NOWe need to determine if the call conveys that outsiders are currently underweighting something the company has already done, and management points to a concrete, already-completed or already-operating piece of the business whose contribution is still largely ahead of reported results. Let's analyze the transcript. Management discusses 2015 results and 2016 guidance. They emphasize stability, strong balance sheet, fee-based contracts, etc. They talk about growth capital in Oklahoma, Permian, Louisiana. They mention specific projects: Riptide plant, Lobo II plant, Ascension Pipeline, etc. But are these already completed? Some are under construction or scheduled to come online later in 2016. For example, Riptide scheduled to come online in first half of 2016, Lobo II in fourth quarter, Ascension Pipeline is being constructed. So these are not yet operating at the time of the call. They are future projects. Management also mentions that they have brought on additional 100 million cubic feet of gas at Cana plant in Q4, and had record volumes in November through January. That is already operating. But is that a recognition gap? They say "we had record volumes" but that is already reflected in results? They are talking about Q4 and early 2016. The call is about Q4 2015 and full year 2015 results. So record volumes in Nov-Jan are part of Q4 and early Q1 2016. But the guidance for 2016 is based on $770 million EBITDA. They don't explicitly say that outsiders are underweighting something already done. Look for management's own claim that the company is perceived or measured incorrectly. Barry Davis says: "We have best-in-class assets positioned in the core of the core across the most attractive plays in the country and we remain confident in our ability to execute on future opportunities from our strong platform of assets and services." That's confidence, not a recognition gap. Mike Garberding discusses balance sheet and financing. He says "We are hyper focused on executing in our core growth areas." He mentions that they reduced capital spending in Oklahoma from $350 million to $180 million by integrating assets and postponing capital. That's about capital efficiency, not about outsiders underweighting. There is a mention of "we have started the process of getting an additional rating from Fitch." That's about credit rating, not about underweighting.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| PFE | Pfizer Inc. | Q4 2023 | 2024-01-30 | F |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| BRX | Brixmor Property Group Inc. | Q1 2023 | 2023-05-02 | A |
| OEC | Orion Engineered Carbons S.A. | Q4 2022 | 2023-02-17 | B+ |
| KEY | KeyCorp | Q3 2022 | 2022-10-20 | B+ |
| KIM | Kimco Realty Corporation | Q2 2018 | 2018-07-26 | B+ |
| HOLX | Hologic, Inc. | Q4 2017 | 2017-11-08 | D |
PRPH · Q1 2023 → YESThe question is: Does management convey that outsiders are currently underweighting something the company has already done, and do they point to at least one concrete, already-completed or already-ope...YES The transcript shows management explicitly framing the current market view as mismatched with the company's actual position: "Anybody that's focused on us for earnings, you invested or are following the wrong company," "we're not an earnings story this year," and "focus less on revenues and earnings. This is a transition year." They repeatedly contrast this with the multi-billion-dollar assets already built and operating, whose contributions are still ramping or largely ahead. Concrete already-real items with meaningful payoff still ahead include: - The manufacturing facility (already at capacity, running nearly 100% YoY growth, with $25M revenue target for 2024 constrained only by capacity expansion this year; estimated $70M valuation next year plus $40M working capital and tens of millions in equipment). - Nebula Genomics (already generating >100% YoY revenue growth via direct-to-consumer sales; in-house whole-genome processing and B2B ramp expected in H2 202 3, particularly Q4, after validations complete in a couple of months).
KEY · Q3 2022 → YESThe question is: Does management convey that OUTSIDERS ARE CURRENTLY UNDERWEIGHTING SOMETHING THE COMPANY HAS ALREADY DONE — and does management answer that gap by pointing to at least one CONCRETE, A...YES Management repeatedly frames its interest-rate-risk positioning as something that “sets Key apart” and creates “unique and significant upside” that is not yet reflected in the market’s view of the company. Chris Gorman states that the $1.2 billion annualized benefit from re-pricing existing short-term Treasuries and swaps “ even in the event that rates remain at current levels” will arrive over the next two years, and Don Kimble confirms the same mechanics and timing. The $9 billion in short-term Treasuries and $26 billion in swaps are already on the balance sheet; the contribution is simply not yet in the reported results.
KIM · Q2 2018 → YESThe question is: Does management convey that outsiders are currently underweighting something the company has already done, and do they point to at least one concrete, already-completed or already-ope...YES Management explicitly frames the public-private pricing disconnect as a gap in how the company is valued versus its actual assets and execution. They point to the already-completed Toys "R" Us liquidation process (22 boxes resolved into OpCo and PropCo leases, with seven OpCo leases already signed and seven PropCo under 18-24 month resolution) as a concrete, already-real item whose rent contribution is still largely ahead in the reported results, with the 70-80 bps impact on occupancy and same-site NOI expected to be recaptured in Q3 and beyond.